Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Taiwan Biobank
2.3. Collection of Study Variables
2.4. Definition of MetS
2.5. Assessment of Betel Nut Chewing
- ‘How many years have you chewed betel nut?’
- ‘How often do you chew betel nut?’ (frequency)
- 1–3 days/month (score = 1);
- 1, 2 days/week (score = 2);
- 3–5 days/week (score = 3);
- Every day (score = 4).
- ‘How many quid a day?’ (daily amount)
- <10 quids (score = 1);
- 10–20 quids (score = 2);
- 21–30 quids (score = 3);
- ≥31 quids (score = 4).
- Cumulative dose = years of chewing betel nut × frequency score × daily score.
2.6. Statistical Analysis
3. Results
3.1. Comparison of Clinical Characteristics among the Participants according to Baseline MetS
3.2. Association between Betel Nut Chewing History with Baseline MetS and Its Components in All Participants
3.3. Association between Duration of Chewing Betel Nut with Baseline MetS and Its Components in Study Participants with Betel Nut Chewing History
3.4. Association between Betel Nut Chewing History with Follow-Up MetS and its Components in Follow-Up Participants without Baseline MetS
3.5. Association between Duration of Chewing Betel Nut with Follow-Up MetS and Its Components in Follow-Up Participants without Baseline MetS with a Betel Nut Chewing History
3.6. Prevalence of Betel Nut Chewing History and Betel Nut Chewing Years According to the Sum of Components of MetS
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Reaven, G.M. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu. Rev. Med. 1993, 44, 121–131. [Google Scholar] [CrossRef] [PubMed]
- Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C.; et al. Diagnosis and Management of the Metabolic Syndrome. Circulation 2005, 112, 2735–2752. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ranasinghe, P.; Mathangasinghe, Y.; Jayawardena, R.; Hills, A.P.; Misra, A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: A systematic review. BMC Public Health 2017, 17, 101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grundy, S.M.; Hansen, B.; Smith, S.C.; Cleeman, J.I.; Kahn, R.A. Clinical Management of Metabolic Syndrome. Circulation 2004, 109, 551–556. [Google Scholar] [CrossRef] [Green Version]
- Mottillo, S.; Filion, K.B.; Genest, J.; Joseph, L.; Pilote, L.; Poirier, P.; Rinfret, S.; Schiffrin, E.L.; Eisenberg, M.J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010, 56, 1113–1132. [Google Scholar] [CrossRef] [Green Version]
- Ford, E.S.; Li, C.; Sattar, N. Metabolic syndrome and incident diabetes: Current state of the evidence. Diabetes Care 2008, 31, 1898–1904. [Google Scholar] [CrossRef] [Green Version]
- Lee, M.K.; Han, K.; Kim, M.K.; Koh, E.S.; Kim, E.S.; Nam, G.E.; Kwon, H.S. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: A nationwide cohort study. Sci. Rep. 2020, 10, 2313. [Google Scholar] [CrossRef]
- Rodriguez-Colon, S.M.; Mo, J.; Duan, Y.; Liu, J.; Caulfield, J.E.; Jin, X.; Liao, D. Metabolic Syndrome Clusters and the Risk of Incident Stroke. Stroke 2009, 40, 200–205. [Google Scholar] [CrossRef] [Green Version]
- Chen, H.-J.; Bai, C.-H.; Yeh, W.-T.; Chiu, H.-C.; Pan, W.-H. Influence of Metabolic Syndrome and General Obesity on the Risk of Ischemic Stroke. Stroke 2006, 37, 1060–1064. [Google Scholar] [CrossRef] [Green Version]
- Vgontzas, A.N.; Bixler, E.O.; Chrousos, G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med. Rev. 2005, 9, 211–224. [Google Scholar] [CrossRef]
- Lim, S.S.; Kakoly, N.S.; Tan, J.W.J.; Fitzgerald, G.; Bahri Khomami, M.; Joham, A.E.; Cooray, S.D.; Misso, M.L.; Norman, R.J.; Harrison, C.L.; et al. Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2019, 20, 339–352. [Google Scholar] [CrossRef] [PubMed]
- Loria, P.; Lonardo, A.; Carulli, L.; Verrone, A.M.; Ricchi, M.; Lombardini, S.; Rudilosso, A.; Ballestri, S.; Carulli, N. Review article: The metabolic syndrome and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2005, 22 (Suppl. S2), 31–36. [Google Scholar] [CrossRef] [PubMed]
- Esposito, K.; Chiodini, P.; Colao, A.; Lenzi, A.; Giugliano, D. Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. Diabetes Care 2012, 35, 2402–2411. [Google Scholar] [CrossRef] [Green Version]
- Winstock, A. Areca nut-abuse liability, dependence and public health. Addict. Biol. 2002, 7, 133–138. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.-H.; Ko, A.M.-S.; Warnakulasuriya, S.; Yin, B.-L.; Sunarjo; Zain, R.B.; Ibrahim, S.O.; Liu, Z.-W.; Li, W.-H.; Zhang, S.-S.; et al. Intercountry prevalences and practices of betel-quid use in south, southeast and eastern asia regions and associated oral preneoplastic disorders: An international collaborative study by asian betel-quid consortium of south and east Asia. Int. J. Cancer 2011, 129, 1741–1751. [Google Scholar] [CrossRef] [Green Version]
- Secretan, B.; Straif, K.; Baan, R.; Grosse, Y.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens—Part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009, 10, 1033–1034. [Google Scholar] [CrossRef]
- Lin, W.-Y.; Pi-Sunyer, F.X.; Liu, C.-S.; Li, T.-C.; Li, C.-I.; Huang, C.-Y.; Lin, C.-C. Betel Nut Chewing Is Strongly Associated with General and Central Obesity in Chinese Male Middle-aged Adults. Obesity 2009, 17, 1247–1254. [Google Scholar] [CrossRef] [Green Version]
- Tseng, C.-H. Betel Nut Chewing Is Associated with Hypertension in Taiwanese Type 2 Diabetic Patients. Hypertens. Res. 2008, 31, 417–423. [Google Scholar] [CrossRef] [Green Version]
- Chou, C.Y.; Cheng, S.-Y.; Liu, J.-H.; Cheng, W.-C.; Kang, I.-M.; Tseng, Y.-H.; Shih, C.-M.; Chen, W. Association between betel-nut chewing and chronic kidney disease in men. Public Health Nutr. 2009, 12, 723–727. [Google Scholar] [CrossRef] [Green Version]
- Lin, W.-Y.; Chiu, T.-Y.; Lee, L.-T.; Lin, C.-C.; Huang, C.-Y.; Huang, K.-C. Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men. Am. J. Clin. Nutr. 2008, 87, 1204–1211. [Google Scholar] [CrossRef] [Green Version]
- Tsai, W.-C.; Wu, M.-T.; Wang, G.-J.; Lee, K.-T.; Lee, C.-H.; Lu, Y.-H.; Yen, H.-W.; Chu, C.-S.; Chen, Y.-T.; Lin, T.-H.; et al. Chewing areca nut increases the risk of coronary artery disease in Taiwanese men: A case-control study. BMC Public Health 2012, 12, 162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamada, T.; Hara, K.; Kadowaki, T. Chewing betel quid and the risk of metabolic disease, cardiovascular disease, and all-cause mortality: A meta-analysis. PLoS ONE 2013, 8, e70679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsai, J.-F.; Jeng, J.-E.; Chuang, L.-Y.; Ho, M.-S.; Ko, Y.-C.; Lin, Z.-Y.; Hsieh, M.-Y.; Chen, S.-C.; Chuang, W.-L.; Wang, L.-Y.; et al. Habitual betel quid chewing as a risk factor for cirrhosis: A case-control study. Medicine 2003, 82, 365–372. [Google Scholar] [CrossRef] [PubMed]
- Boucher, B.J.; Ewen, S.W.; Stowers, J.M. Betel nut (Areca catechu) consumption and the induction of glucose intolerance in adult CD1 mice and in their F1 and F2 offspring. Diabetologia 1994, 37, 49–55. [Google Scholar] [CrossRef]
- Tung, T.-H.; Chiu, Y.-H.; Chen, L.-S.; Wu, H.-M.; Boucher, B.-J.; Chen, T.H. A population-based study of the association between areca nut chewing and type 2 diabetes mellitus in men (Keelung Community-based Integrated Screening programme No. 2). Diabetologia 2004, 47, 1776–1781. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guh, J.-Y.; Chuang, L.-Y.; Chen, H.-C. Betel-quid use is associated with the risk of the metabolic syndrome in adults. Am. J. Clin. Nutr. 2006, 83, 1313–1320. [Google Scholar] [CrossRef]
- Shafique, K.; Zafar, M.; Ahmed, Z.; Khan, N.A.; Mughal, M.A.; Imtiaz, F. Areca nut chewing and metabolic syndrome: Evidence of a harmful relationship. Nutr. J. 2013, 12, 67. [Google Scholar] [CrossRef] [Green Version]
- Javed, F.; Al-Hezaimi, K.; Warnakulasuriya, S. Areca-nut chewing habit is a significant risk factor for metabolic syndrome: A systematic review. J.Nutr. Health Aging 2012, 16, 445–448. [Google Scholar] [CrossRef]
- Hsieh, T.-J.; Hsieh, P.-C.; Wu, M.-T.; Chang, W.-C.; Hsiao, P.-J.; Lin, K.-D.; Chou, P.-C.; Shin, S.-J. Betel nut extract and arecoline block insulin signaling and lipid storage in 3T3-L1 adipocytes. Cell Biol. Toxicol. 2011, 27, 397–411. [Google Scholar] [CrossRef]
- Chen, C.-H.; Yang, J.-H.; Chiang, C.W.K.; Hsiung, C.-N.; Wu, P.-E.; Chang, L.-C.; Chu, H.-W.; Chang, J.; Song, I.-W.; Yang, S.-L.; et al. Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. Hum. Mol. Genet. 2016, 25, 5321–5331. [Google Scholar] [CrossRef] [Green Version]
- Fan, C.-T.; Hung, T.-H.; Yeh, C.-K. Taiwan Regulation of Biobanks. J. Law Med. Ethics A J. Am. Soc. Law Med. Ethics 2015, 43, 816–826. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef]
- Isomaa, B.; Henricsson, M.; Almgren, P.; Tuomi, T.; Taskinen, M.R.; Groop, L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44, 1148–1154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tan, C.-E.; Ma, S.; Wai, D.; Chew, S.-K.; Tai, E.-S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004, 27, 1182–1186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, F.-M.; Chang, D.-M.; Chen, M.-P.; Tsai, J.-C.; Yang, Y.-H.; Shieh, T.-Y.; Shin, S.-J.; Chen, T.-H.; Tai, T.-Y.; Lee, Y.-J. Areca nut chewing is associated with metabolic syndrome: Role of tumor necrosis factor-alpha, leptin, and white blood cell count in betel nut chewing-related metabolic derangements. Diabetes Care 2006, 29, 1714. [Google Scholar] [CrossRef] [Green Version]
- Lee, B.-J.; Chan, M.-Y.; Hsiao, H.-Y.; Chang, C.-H.; Hsu, L.-P.; Lin, P.-T. Relationship of Oxidative Stress, Inflammation, and the Risk of Metabolic Syndrome in Patients with Oral Cancer. Oxidative Med. Cell. Longev. 2018, 2018, 9303094. [Google Scholar] [CrossRef]
- Yen, A.M.; Chiu, Y.-H.; Chen, L.-S.; Wu, H.-M.; Huang, C.-C.; Boucher, B.-J.; Chen, T.H. A population-based study of the association between betel-quid chewing and the metabolic syndrome in men. Am. J. Clin. Nutr. 2006, 83, 1153–1160. [Google Scholar] [CrossRef] [Green Version]
- Boucher, B.J.; Mannan, N. Metabolic effects of the consumption of Areca catechu. Addict. Biol. 2002, 7, 103–110. [Google Scholar] [CrossRef]
- Giri, S.; Idle, J.R.; Chen, C.; Zabriskie, T.M.; Krausz, K.W.; Gonzalez, F.J. A Metabolomic Approach to the Metabolism of the Areca Nut Alkaloids Arecoline and Arecaidine in the Mouse. Chem. Res. Toxicol. 2006, 19, 818–827. [Google Scholar] [CrossRef] [Green Version]
- Pownall, H.J.; Ballantyne, C.M.; Kimball, K.T.; Simpson, S.L.; Yeshurun, D.; Gotto, A.M., Jr. Effect of Moderate Alcohol Consumption on Hypertriglyceridemia: A Study in the Fasting State. Arch. Intern. Med. 1999, 159, 981–987. [Google Scholar] [CrossRef] [Green Version]
- Hsu, H.-F.; Tsou, T.-C.; Chao, H.-R.; Shy, C.-G.; Kuo, Y.-T.; Tsai, F.-Y.; Yeh, S.-C.; Ko, Y.-C. Effects of arecoline on adipogenesis, lipolysis, and glucose uptake of adipocytes-A possible role of betel-quid chewing in metabolic syndrome. Toxicol. Appl. Pharmacol. 2010, 245, 370–377. [Google Scholar] [CrossRef] [PubMed]
- Chu, N.S. Cardiovascular responses to betel chewing. J. Formos. Med. Assoc. 1993, 92, 835–837. [Google Scholar] [PubMed]
- Chiou, S.S.; Kuo, C.D. Effect of chewing a single betel-quid on autonomic nervous modulation in healthy young adults. J. Psychopharmacol. 2008, 22, 910–917. [Google Scholar] [CrossRef]
- Arambewela, L.; Arawwawala, L.; Ratnasooriya, W. Antidiabetic activities of aqueous and ethanolic extracts of Piper betle leaves in rats. J. Ethnopharmacol. 2005, 102, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Musdja, M.Y.; Nurdin, A.; Musir, A. Antidiabetic effect and glucose tolerance of areca nut (Areca catechu) seed ethanol extract on alloxan-induced diabetic male rats. IOP Conf. Ser. Earth Environ. Sci. 2020, 462, 012036. [Google Scholar] [CrossRef]
- Cardosa, S.R.; Ogunkolade, B.W.; Lowe, R.; Savage, E.; Mein, C.A.; Boucher, B.J.; Hitman, G.A. Areca catechu-(Betel-nut)-induced whole transcriptome changes in a human monocyte cell line that may have relevance to diabetes and obesity; A pilot study. BMC Endocr. Disord. 2021, 21, 165. [Google Scholar] [CrossRef] [PubMed]
Characteristics | MetS (−) (n = 94,043) | MetS (+) (n = 27,380) | p |
---|---|---|---|
Age (year) | 48.8 ± 10.9 | 53.6 ± 10.1 | <0.001 |
Male gender (%) | 33.7 | 43.7 | <0.001 |
DM (%) | 2.5 | 14.3 | <0.001 |
Hypertension (%) | 6.9 | 30.6 | <0.001 |
Betel nut chewing history (%) | 4.8 | 10.4 | <0.001 |
Smoking history (%) | 25.3 | 33.9 | <0.001 |
Alcohol drinking history (%) | 7.5 | 12.0 | <0.001 |
Regular exercise habits (%) | 40.5 | 40.8 | 0.33 |
BMI (kg/m2) | 23.3 ± 3.3 | 27.3 ± 3.8 | <0.001 |
Waist circumference (cm) | 80.8 ± 9.1 | 91.9 ± 9.1 | <0.001 |
Laboratory parameters | <0.001 | ||
Fasting glucose (mg/dL) | 92.0 ± 13.3 | 109.2 ± 32.6 | <0.001 |
Triglyceride (mg/dL) | 92.6 ± 53.2 | 194.8 ± 146.3 | <0.001 |
Total cholesterol (mg/dL) | 194.5 ±34.8 | 199.6 ± 38.9 | <0.001 |
HDL-cholesterol (mg/dL) | 57.6 ± 12.9 | 44.2 ± 9.5 | <0.001 |
LDL-cholesterol (mg/dL) | 120.0 ± 31.1 | 124.1 ± 33.8 | <0.001 |
eGFR (mL/min/1.73 m2) | 104.7 ± 23.5 | 98.4 ± 24.4 | <0.001 |
Uric acid (mg/dL) | 5.2 ± 1.3 | 6.1 ± 1.5 | <0.001 |
Variables | Baseline MetS | Baseline Abdominal Obesity | Baseline Hypertriglyceridemia | Baseline Low HDL-Cholesterol | Baseline Hyperglycemia | Baseline High Blood Pressure |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Betel nut chewing history | 1.629 (1.535–1.730) ** | 1.550 (1.465–1.640) ** | 1.488 (1.399–1.582) ** | 1.529 (1.435–1.630) ** | 1.222 (1.151–1.297) ** | 1.139 (1.075–1.206) ** |
Age (per 1 year) | 1.051 (1.049–1.053) ** | 1.029 (1.027–1.030) ** | 1.015 (1.013–1.016) ** | 1.019 (1.017–1.020) ** | 1.072 (1.070–1.074) ** | 1.076 (1.074–1.077) ** |
Male (vs. female) | 0.653 (0.627–0.680) ** | 0.258 (0.248–0.267) ** | 1.463 (1.403–1.526) ** | 0.257 (0.247–0.268) ** | 1.430 (1.374–1.489) ** | 1.720 (1.660–1.783) ** |
Smoking history | 1.175 (1.130–1.222) ** | 1.132 (1.096–1.171) ** | 1.215 (1.168–1.265) ** | 1.209 (1.164–1.256) ** | 1.086 (1.044–1.130) ** | 0.925 (0.892–0.959) ** |
Alcohol drinking history | 1.052 (0.998–1.108) | 1.121 (1.070–1.175) ** | 0.918 (0.870–0.969) * | 0.754 (0.712–0.799) ** | 1.258 (1.195–1.324) ** | 1.299 (1.237–1.364) ** |
Regular exercise habits | 0.710 (0.688–0.732) ** | 0.737 (0.718–0.757) ** | 0.684 (0.662–0.707) ** | 0.761 (0.738–0.784) ** | 0.869 (0.842–0.896) ** | 0.943 (0.917–0.970) ** |
Total cholesterol (per 1 mg/dL) | 1.002 (1.001–1.003) ** | 0.989 (0.988–0.990) ** | 1.042 (1.041–1.043) ** | 0.954 (0.953–0.955) ** | 1.000 (0.999–1.000) | 1.000 (0.999–1.001) |
LDL-cholesterol (per 1 mg/dL) | 0.998 (0.9970.999) ** | 1.016 (1.015–1.017) ** | 0.966 (0.965–0.967) ** | 1.042 (1.041–1.044) ** | 1.001 (1.000–1.002) | 1.002 (1.001–1.002) ** |
eGFR (per 1 mL/min/1.73 m2) | 1.005 (1.004–1.006) ** | 1.006 (1.005–1.006) ** | 1.005 (1.004–1.005) ** | 1.004 (1.003–1.004) ** | 1.007 (1.006–1.007) ** | 1.000 (0.999–1.001) |
Uric acid (per 1 mg/dL) | 1.690 (1.669–1.712) ** | 1.611 (1.592–1.629) ** | 1.639 (1.617–1.661) ** | 1.532 (1.513–1.551) ** | 1.249 (1.234–1.265) ** | 1.338 (1.323–1.353) ** |
Variables | Baseline MetS | Baseline Abdominal Obesity | Baseline Hypertriglyceridemia | Baseline Low HDL-Cholesterol | Baseline Hyperglycemia | Baseline High Blood Pressure |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Betel nut chewing years (per 1 year) | 1.008 (1.004–1.013) ** | 1.006 (1.001–1.010) * | 1.011 (1.006–1.016) ** | 1.012 (1.007–1.017) ** | 1.002 (0.998–1.007) | 0.999 (0.994–1.003) |
Age (per 1 year) | 1.028 (1.022–1.033) ** | 1.011 (1.006–1.016) ** | 0.988 (0.982–0.993) ** | 0.995 (0.990–1.001) | 1.054 (1.048–1.061) ** | 1.055 (1.049–1.061) ** |
Male (vs. female) | 0.886 (0.660–1.189) | 0.343 (0.257–0.459) ** | 1.734 (1.247–2.411) * | 0.515 (0.386–0.687) ** | 1.587 (1.147–2.195) * | 1.669 (1.238–2.250) * |
Smoking history | 0.985 (0.800–1.213) | 0.837 (0.683–1.025) | 1.318 (1.048–1.659) * | 1.296 (1.028–1.633) * | 0.964 (0.777–1.195) | 0.814 (0.660–1.004) |
Alcohol drinking history | 1.117 (1.010–1.235) * | 1.059 (0.962–1.167) | 0.970 (0.870–1.083) | 0.659 (0.591–0.735) ** | 1.322 (1.1931–0.465) ** | 1.501 (1.358–1.659) ** |
Regular exercise habits | 0.798 (0.718–0.888) ** | 0.824 (0.744–0.912) ** | 0.679 (0.605–0.763) ** | 0.692 (0.617–0.777) ** | 0.914 (0.820–1.018) | 1.141 (1.028–1.267) * |
Total cholesterol (per 1 mg/dL) | 1.012 (1.010–1.015) ** | 1.000 (0.998–1.002) | 1.061 (1.057–1.065) ** | 0.992 (0.990–0.995) ** | 1.005 (1.003–1.007) ** | 1.004 (1.002–1.006) ** |
LDL-cholesterol (per 1 mg/dL) | 0.986 (0.983–0.988) ** | 1.002 (1.000–1.005) | 0.944 (0.940–0.948) ** | 0.996 (0.993–0.999) * | 0.995 (0.992–0.997) ** | 0.995 (0.993–0.998) ** |
eGFR (per 1 mL/min/1.73 m2) | 0.999 (0.996–1.001) | 1.000 (0.998–1.002) | 0.998 (0.995–1.000) | 1.000 (0.997–1.002) | 1.005 (1.002–1.007) ** | 0.998 (0.995–1.000) |
Uric acid (per 1 mg/dL) | 1.258 (1.213–1.305) ** | 1.251 (1.207–1.296) ** | 1.241 (1.192–1.291) ** | 1.203 (1.158–1.250) ** | 1.022 (0.985–1.060) | 1.183 (1.141–1.227) ** |
Variables | Follow-Up MetS | Follow-Up Abdominal Obesity | Follow-Up Hypertriglyceridemia | Follow-Up Low HDL-Cholesterol | Follow-Up Hyperglycemia | Follow-Up High Blood Pressure |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Betel nut chewing history | 1.352 (1.134–1.612) * | 1.197 (1.035–1.384) * | 1.326 (1.130–1.556) * | 1.345 (1.113–1.626) * | 1.153 (0.982–1.353) | 0.998 (0.865–1.152) |
Age (per 1 year) | 1.033 (1.029–1.038) ** | 1.018 (1.015–1.021) ** | 0.996 (0.992–1.000) | 1.010 (1.006–1.014) ** | 1.058 (1.053–1.063) ** | 1.074 (1.070–1.078) ** |
Male (vs. female) | 0.502 (0.446–0.565) ** | 0.198 (0.181–0.217) ** | 1.269 (1.137–1.416) ** | 0.239 (0.213–0.269) ** | 1.513 (1.361–1.682) ** | 1.773 (1.624–1.936) ** |
Smoking history | 1.142 (1.017–1.283) * | 1.135 (1.041–1.238) * | 1.110 (0.996–1.235) | 1.144 (1.023–1.280) * | 0.973 (0.875–1.083) | 0.930 (0.850–1.018) |
Alcohol drinking history | 1.085 (0.941–1.252) | 1.092 (0.978–1.220) | 0.960 (0.841–1.096) | 0.786 (0.671–0.920) * | 1.255 (1.106–1.423) ** | 1.305 (1.167–1.458) ** |
Regular exercise habits | 0.790 (0.726–0.861) ** | 0.754 (0.708–0.802) ** | 0.753 (0.693–0.819) ** | 0.836 (0.771–0.907) ** | 0.956 (0.883–1.035) | 0.933 (0.874–0.996) * |
Total cholesterol (per 1 mg/dL) | 0.980 (0.977–0.983) ** | 0.985 (0.983–0.987) ** | 1.013 (1.011–1.016) ** | 0.925 (0.922–0.928) ** | 0.995 (0.992–0.997) ** | 0.998 (0.996–1.000) |
LDL-cholesterol (per 1 mg/dL) | 1.026 (1.023–1.030) ** | 1.022 (1.019–1.024) ** | 0.997 (0.994–0.999) * | 1.084 (1.079–1.088) ** | 1.007 (1.004–1.010) ** | 1.004 (1.002–1.007) ** |
eGFR (per 1 mL/min/1.73 m2) | 1.004 (1.002–1.006) ** | 1.003 (1.002–1.005) ** | 1.001 (0.999–1.003) | 1.003 (1.001–1.005) ** | 1.006 (1.004–1.007) ** | 1.001 (1.000–1.003) |
Uric acid (per 1 mg/dL) | 1.483 (1.430–1.537) ** | 1.441 (1.401–1.482) ** | 1.366 (1.319–1.414) ** | 1.279 (1.235–1.325) ** | 1.161 (1.123–1.201) ** | 1.254 (1.219–1.290) ** |
Variables | Follow-Up MetS | Follow-Up Abdominal obesity | Follow-Up Hypertriglyceridemia | Follow-Up Low HDL-Cholesterol | Follow-Up Hyperglycemia | Follow-Up High Blood Pressure |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Betel nut chewing years (per 1 year) | 1.021 (1.008–1.035) * | 1.012 (1.001–1.024) * | 1.019 (1.006–1.032) * | 1.015 (1.000–1.030) | 1.003 (0.991–1.015) | 1.007 (0.996–1.018) |
Age (per 1 year) | 1.005 (0.988–1.023) | 1.005 (0.991–1.019) | 0.961 (0.946–0.976) ** | 0.985 (0.967–1.003) | 1.045 (1.028–1.061) ** | 1.052 (1.038–1.067) ** |
Male (vs. female) | 0.501 (0.198–1.265) | 0.152 (0.065–0.358) ** | 1.101 (0.448–2.706) | 0.707 (0.264–1.894) | 1.999 (0.656–6.086) | 0.859 (0.378–1.952) |
Smoking history | 1.296 (0.639–2.628) | 1.277 (0.706–2.311) | 0.735 (0.402–1.342) | 0.782 (0.381–1.601) | 1.107 (0.581–2.109) | 1.194 (0.680–2.096) |
Alcohol drinking history | 0.909 (0.666–1.241) | 1.000 (0.771–1.298) | 0.745 (0.556–0.999) * | 0.556 (0.396–0.780) * | 1.319 (0.993–1.752) | 1.456 (1.130–1.878) * |
Regular exercise habits | 0.776 (0.560–1.075) | 0.881 (0.672–1.156) | 0.693 (0.509–0.943) * | 0.826 (0.580–1.175) | 0.971 (0.725–1.301) | 1.053 (0.809–1.369) |
Total cholesterol (per 1 mg/dL) | 1.008 (1.000–1.017) | 0.991 (0.983–0.999) * | 1.034 (1.025–1.043) ** | 0.968 (0.956–0.980) ** | 1.003 (0.995–1.012) | 1.004 (0.997–1.001) |
LDL-cholesterol (per 1 mg/dL) | 0.992 (0.982–1.001) | 1.014 (1.005–1.023) * | 0.972 (0.962–0.981) ** | 1.031 (1.017–1.045) ** | 1.000 (0.991–1.009) | 0.998 (0.990–1.006) |
eGFR (per 1 mL/min/1.73 m2) | 0.999 (0.991–1.007) | 1.001 (0.994–1.007) | 0.996 (0.988–1.003) | 1.003 (0.995–1.012) | 1.000 (0.992–1.007) | 0.998 (0.992–1.005) |
Uric acid (per 1 mg/dL) | 1.258 (1.117–1.416) ** | 1.199 (1.084–1.327) ** | 1.181 (1.056–1.322) * | 1.110 (0.976–1.262) | 0.927 (0.831–1.034) | 1.147 (1.040–1.266) * |
0 | 1 | 2 | 3 | 4 | 5 | p | |
---|---|---|---|---|---|---|---|
All participants (n = 121,423) | n = 34,569 | n = 33,492 | n = 25,982 | n = 16,697 | n = 8166 | n = 2417 | |
Betel nut chewing history (%) | 3.3 | 4.8 | 6.8 | 9.7 | 11.5 | 11.4 | <0.001 |
All participants with betel nut chewing history (n = 7355) | n = 1144 | n = 1607 | n = 1759 | n = 1621 | n = 936 | n = 288 | |
Betel nut chewing years | 12.4 ± 10.7 | 13.2 ± 10.6 | 14.4 ± 11.3 | 15.1 ± 11.4 | 15.8 ± 11.2 | 15.7 ± 1.0 | <0.001 |
Follow-up participants without baseline MetS (n = 21,150) | n = 6039 | n = 6940 | n = 5173 | n = 2235 | n = 651 | n = 112 | |
Betel nut chewing history (%) | 3.8 | 5.1 | 6.4 | 7.6 | 8.8 | 7.1 | <0.001 |
Follow-up participants without baseline MetS with a betel nut chewing history (n = 1146) | n = 220 | n = 343 | n = 321 | n = 158 | n = 76 | n = 28 | |
Betel nut chewing years | 12.7 ± 10.0 | 14.8 ± 11.0 | 14.9 ± 11.9 | 17.5 ± 12.4 | 17.5 ± 10.8 | 15.3 ± 13.1 | 0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, Y.-C.; Geng, J.-H.; Wu, P.-Y.; Huang, J.-C.; Chen, S.-C.; Chang, J.-M.; Chen, H.-C. Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation. Nutrients 2022, 14, 1018. https://doi.org/10.3390/nu14051018
Huang Y-C, Geng J-H, Wu P-Y, Huang J-C, Chen S-C, Chang J-M, Chen H-C. Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation. Nutrients. 2022; 14(5):1018. https://doi.org/10.3390/nu14051018
Chicago/Turabian StyleHuang, Ya-Chin, Jiun-Hung Geng, Pei-Yu Wu, Jiun-Chi Huang, Szu-Chia Chen, Jer-Ming Chang, and Hung-Chun Chen. 2022. "Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation" Nutrients 14, no. 5: 1018. https://doi.org/10.3390/nu14051018
APA StyleHuang, Y. -C., Geng, J. -H., Wu, P. -Y., Huang, J. -C., Chen, S. -C., Chang, J. -M., & Chen, H. -C. (2022). Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation. Nutrients, 14(5), 1018. https://doi.org/10.3390/nu14051018